The therapeutic effects of anti-BAFF therapy with Belimumab have been demonstrated in patients with SLE, based on two large randomized controlled trials, BLISS 52 and BLISS 76 [129]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.